Respiri Management

Management criteria checks 1/4

Respiri's CEO is Marjan Mikel, appointed in Dec 2019, has a tenure of 4.92 years. total yearly compensation is A$758.38K, comprised of 56.5% salary and 43.5% bonuses, including company stock and options. directly owns 0.35% of the company’s shares, worth A$373.81K. The average tenure of the management team and the board of directors is 3.4 years and 1.8 years respectively.

Key information

Marjan Mikel

Chief executive officer

AU$758.4k

Total compensation

CEO salary percentage	56.5%
CEO tenure	4.9yrs
CEO ownership	0.4%
Management average tenure	3.4yrs
Board average tenure	1.8yrs

Recent management updates

Respiri Limited's (ASX:RSH) CEO Will Probably Find It Hard To See A Huge Raise This Year

Nov 08

Recent updates

Respiri Limited's (ASX:RSH) CEO Will Probably Find It Hard To See A Huge Raise This Year

Nov 08

CEO Compensation Analysis

How has Marjan Mikel's remuneration changed compared to Respiri's earnings?
Date	Total Compensation	Salary	Company Earnings
Jun 30 2024	AU$758k	AU$428k	-AU$7m
Mar 31 2024	n/a	n/a	-AU$7m
Dec 31 2023	n/a	n/a	-AU$6m
Sep 30 2023	n/a	n/a	-AU$6m
Jun 30 2023	AU$570k	AU$428k	-AU$6m
Mar 31 2023	n/a	n/a	-AU$6m
Dec 31 2022	n/a	n/a	-AU$6m
Sep 30 2022	n/a	n/a	-AU$6m
Jun 30 2022	AU$607k	AU$428k	-AU$7m
Mar 31 2022	n/a	n/a	-AU$7m
Dec 31 2021	n/a	n/a	-AU$8m
Sep 30 2021	n/a	n/a	-AU$9m
Jun 30 2021	AU$2m	AU$428k	-AU$11m
Mar 31 2021	n/a	n/a	-AU$12m
Dec 31 2020	n/a	n/a	-AU$12m
Sep 30 2020	n/a	n/a	-AU$10m
Jun 30 2020	AU$2m	AU$187k	-AU$7m

Compensation vs Market: Marjan's total compensation ($USD493.10K) is above average for companies of similar size in the Australian market ($USD298.50K).

Compensation vs Earnings: Marjan's compensation has increased whilst the company is unprofitable.

CEO

Marjan Mikel

4.9yrs

Tenure

AU$758,383

Compensation

Mr. Marjan Mikel, M.Com, BSc (Hons), Dip Ed, MAICD), serves as Chief Executive Officer and Managing Director at Respiri Limited since December 2, 2019 and serves as its Executive Director since November 25...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Nicholas Smedley	Executive Chairman	5.1yrs	AU$487.75k	1.26% A$ 1.3m
Marjan Mikel	CEO, MD & Executive Director	4.9yrs	AU$758.38k	0.35% A$ 373.8k
Peter Hildebrandt	Chief Operations Officer	4yrs	AU$276.55k	no data
George Vlachodimitropoulos	Chief Technology Officer	3.3yrs	AU$284.75k	no data
Samaneh Shirazi	Chief Research Officer	5.8yrs	AU$208.01k	no data
Theo Antonopoulos	Chief Commercial Officer	3.4yrs	AU$302.66k	no data
William Sigsbee	Head of US Operations & Chief Commercial Officer for the US market	1.6yrs	no data	no data
Justin Mouchacca	Joint Company Secretary	less than a year	no data	no data
Nova Taylor	Joint Company Secretary	less than a year	no data	no data
Noam Gavriely	Medical & Scientific Advisor	no data	AU$310.61k	no data
Simon Godfrey	Medical & Scientific Advisor	no data	no data	no data

3.4yrs

Average Tenure

Experienced Management: RSH's management team is considered experienced (3.4 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Nicholas Smedley	Executive Chairman	5.1yrs	AU$487.75k	1.26% A$ 1.3m
Marjan Mikel	CEO, MD & Executive Director	5yrs	AU$758.38k	0.35% A$ 373.8k
Gerard Criner	Member of Medical Advisory Board	1.8yrs	no data	no data
William Krimsky	Chair of Medical Advisory Board	1.8yrs	no data	no data
Bruce Thompson	Member of Medical & Scientific Advisory Board	no data	AU$1.47k	no data
Stephen Selinger	Member of Medical Advisory Board	1.8yrs	no data	no data
Jonathan Hovda	Member of Medical Advisory Board	1.8yrs	no data	no data
Tom Takubo	Non-Executive Director	less than a year	no data	no data

1.8yrs

Average Tenure

Experienced Board: RSH's board of directors are not considered experienced ( 1.8 years average tenure), which suggests a new board.

Respiri Management

Management criteria checks 1/4

Key information

Recent management updates

Respiri Limited, Annual General Meeting, Nov 20, 2024

Respiri Limited Announces Executive Changes

Less than half of directors are independent

Respiri Limited's (ASX:RSH) CEO Will Probably Find It Hard To See A Huge Raise This Year

Respiri Limited, Annual General Meeting, Nov 15, 2023

Respiri Limited Appoints Brian Leedman as Non-Executive Director

Recent updates

Respiri Limited, Annual General Meeting, Nov 20, 2024

Full year 2024 earnings released: AU$0.007 loss per share (vs AU$0.007 loss in FY 2023)

Respiri Limited has filed a Follow-on Equity Offering in the amount of AUD 3 million.

New major risk - Shareholder dilution

New major risk - Share price stability

Respiri Limited has filed a Follow-on Equity Offering in the amount of AUD 1.6 million.

Respiri Limited Announces Executive Changes

New major risk - Share price stability

Respiri Limited has completed a Follow-on Equity Offering in the amount of AUD 1.3876 million.

Respiri Limited has filed a Follow-on Equity Offering in the amount of AUD 1.5 million.

Less than half of directors are independent

Respiri Limited's (ASX:RSH) CEO Will Probably Find It Hard To See A Huge Raise This Year

Respiri Limited, Annual General Meeting, Nov 15, 2023

Full year 2023 earnings released: AU$0.007 loss per share (vs AU$0.009 loss in FY 2022)

New major risk - Revenue and earnings growth

New minor risk - Financial data availability

New minor risk - Share price stability

Respiri Limited Appoints Brian Leedman as Non-Executive Director

First half 2023 earnings released: AU$0.003 loss per share (vs AU$0.004 loss in 1H 2022)

Respiri Limited Announces Arkansas Heart Hospital Commences Patients on Wheezo RPM

Respiri Limited Announces Minnesota Lung Center Wheezo Rpm Pilot Program Patient Selection Has Been Finalised and Patient Onboarding Has Successfully Commence

No independent directors

Respiri Announces First Patients Enrolled into Wheezo® Remote Patient Monitoring Programs, Further Validating USA Business Model

Respiri Limited, Annual General Meeting, Nov 15, 2022

Full year 2022 earnings released

We're Keeping An Eye On Respiri's (ASX:RSH) Cash Burn Rate

Respiri Limited Announces Executive Changes

Respiri Limited Announces New £2 Million NIHR-Funded UK Paediatric Asthma Clinical Trial with wheezo

Respiri Limited Appoints Brad Snow as A Non-Executive Director

Respiri Limited Appoints Brad Snow as A Non-Executive Director

Here's Why We're Watching Respiri's (ASX:RSH) Cash Burn Situation

Respiri Limited Announces Resignation of Director of Dr. Thomas Duthy

First half 2022 earnings: Revenues and EPS in line with analyst expectations

Here's Why We're Watching Respiri's (ASX:RSH) Cash Burn Situation

Here's Why We're Watching Respiri's (ASX:RSH) Cash Burn Situation

Full year 2021 earnings released: AU$0.016 loss per share (vs AU$0.013 loss in FY 2020)

Respiri Limited Announces Wheezo Registered and Approved for Sale in the UK Market

We Think Respiri (ASX:RSH) Can Afford To Drive Business Growth

Insider recently bought AU$95k worth of stock

Respiri (ASX:RSH) Is In A Good Position To Deliver On Growth Plans

Respiri Limited Announces New Partnership with Pharmacy 4 Less Banner Group

Respiri Limited Holds Media Events to Mark the Launch of Wheezo

Respiri Limited, Annual General Meeting, Dec 16, 2020

Respiri Limited Files Additional Patent Application

Respiri Limited Announces A Partnership with Entech Electronics for the Global Supply of the Ground Breaking Wheezo

Respiri Limited to Report Fiscal Year 2020 Results on Aug 25, 2020

Respiri Limited announced that it expects to receive AUD 0.09 million in funding

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Board Members

Average Tenure